Clinical trial
Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial
NCT03227419 is registered in ClinicalTrials.gov with Lille Catholic University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial
- Lead sponsor
- Lille Catholic University
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- January 22, 2018
- Completion date
- November 30, 2024
- Enrollment
- 224 (estimated)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.